Fecal Transplantation in Hematopoietic Transplantation.
作者信息
Peled Jonathan U, van den Brink Marcel R M
机构信息
Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Weill Cornell College of Medicine, New York, NY.
出版信息
J Clin Oncol. 2023 Dec 1;41(34):5320-5323. doi: 10.1200/JCO.23.01169. Epub 2023 Oct 23.
Abstract
摘要
相似文献
1
Fecal Transplantation in Hematopoietic Transplantation.造血移植中的粪便移植
J Clin Oncol. 2023 Dec 1;41(34):5320-5323. doi: 10.1200/JCO.23.01169. Epub 2023 Oct 23.
2
Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft--host-disease.反复进行粪便微生物群移植可减轻急性难治性胃肠道移植物抗宿主病中的腹泻，并导致粪便微生物群的持续变化。
Haematologica. 2017 May;102(5):e210-e213. doi: 10.3324/haematol.2016.154351. Epub 2017 Feb 2.
3
Fecal microbiota transplantation in hematopoietic cell transplant and cellular therapy recipients: lessons learned and the path forward.造血细胞移植和细胞治疗受者的粪便微生物移植：经验教训和未来发展方向。
Gut Microbes. 2023 Jan-Dec;15(1):2229567. doi: 10.1080/19490976.2023.2229567.
4
[Fecal microbiota transplantation for patients with refractory diarrhea after allogeneic hematopoietic stem cell transplantation].异基因造血干细胞移植后难治性腹泻患者的粪便微生物群移植
Zhonghua Xue Ye Xue Za Zhi. 2019 Oct 14;40(10):853-855. doi: 10.3760/cma.j.issn.0253-2727.2019.10.011.
5
[Clinical study of 19 cases of steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with fecal microbiota transplantation].[粪便微生物群移植治疗异基因造血干细胞移植后19例类固醇难治性胃肠道急性移植物抗宿主病的临床研究]
Zhonghua Xue Ye Xue Za Zhi. 2023 May 14;44(5):401-407. doi: 10.3760/cma.j.issn.0253-2727.2023.05.008.
6
Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation.靶向肠道微生物组：造血干细胞移植的新兴趋势。
Blood Rev. 2021 Jul;48:100790. doi: 10.1016/j.blre.2020.100790. Epub 2020 Dec 26.
7
[Intestinal microbiota and allogeneic stem cell transplantation].[肠道微生物群与异基因干细胞移植]
Bull Cancer. 2020 Jan;107(1):72-83. doi: 10.1016/j.bulcan.2019.08.014. Epub 2019 Sep 30.
8
[How I treat gastrointestinal tract acute graft versus host disease with fecal microbiota transplantation].[我如何通过粪便微生物群移植治疗胃肠道急性移植物抗宿主病]
Zhonghua Xue Ye Xue Za Zhi. 2022 May 14;43(5):365-369. doi: 10.3760/cma.j.issn.0253-2727.2022.05.003.
9
Fecal Microbiota Transplantation for Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Expanding the Horizon into Pediatrics.异基因造血细胞移植后急性移植物抗宿主病的粪便微生物移植：将视野扩展至儿科。
Transplant Cell Ther. 2023 Aug;29(8):484-491. doi: 10.1016/j.jtct.2023.05.007. Epub 2023 May 10.
10
Fecal Microbiota Transplantation: Restoring the Injured Microbiome after Allogeneic Hematopoietic Cell Transplantation.粪便微生物移植：异基因造血细胞移植后恢复受损的微生物组。
Biol Blood Marrow Transplant. 2019 Jan;25(1):e17-e22. doi: 10.1016/j.bbmt.2018.10.022. Epub 2018 Nov 5.
引用本文的文献
1
A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study.一项关于使用封装粪菌移植减少异基因造血干细胞移植副作用的双盲、随机、安慰剂对照试验的研究方案：HSCT-BIOME研究。
BMC Cancer. 2025 Apr 10;25(1):656. doi: 10.1186/s12885-025-14057-4.
本文引用的文献
1
High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients.癌症患者的药物、微生物组和死亡率之间关联的高分辨率分析。
Cell. 2023 Jun 8;186(12):2705-2718.e17. doi: 10.1016/j.cell.2023.05.007.
2
Key determinants of success in fecal microbiota transplantation: From microbiome to clinic.粪便微生物群移植成功的关键决定因素：从微生物组学到临床。
Cell Host Microbe. 2023 May 10;31(5):712-733. doi: 10.1016/j.chom.2023.03.020.
3
Impact of the Microbiota on Viral Infections.微生物群对病毒感染的影响。
Annu Rev Virol. 2023 Sep 29;10(1):371-395. doi: 10.1146/annurev-virology-111821-115754. Epub 2023 Apr 18.
4
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD.粪菌移植联合芦可替尼作为肠道类固醇难治性急性移植物抗宿主病的挽救治疗方法。
Exp Hematol Oncol. 2022 Nov 9;11(1):96. doi: 10.1186/s40164-022-00350-6.
5
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.RBX2660 在 PUNCH CD3 中的疗效和安全性：一项 III 期、随机、双盲、安慰剂对照试验，采用贝叶斯主要分析预防复发性艰难梭菌感染。
Drugs. 2022 Oct;82(15):1527-1538. doi: 10.1007/s40265-022-01797-x. Epub 2022 Oct 26.
6
Intestinal microbiota score could predict survival following allogeneic hematopoietic stem cell transplantation.肠道微生物群评分可预测异基因造血干细胞移植后的生存率。
Ann Hematol. 2022 Jun;101(6):1283-1294. doi: 10.1007/s00277-022-04817-8. Epub 2022 Mar 25.
7
Human gut bacteria produce Τ17-modulating bile acid metabolites.人体肠道细菌产生调节 T17 型细胞的胆汁酸代谢物。
Nature. 2022 Mar;603(7903):907-912. doi: 10.1038/s41586-022-04480-z. Epub 2022 Mar 16.
8
Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant.异基因造血移植后，早期肠道微生物特征与 CD4 T 细胞恢复相关。
Blood. 2022 May 5;139(18):2758-2769. doi: 10.1182/blood.2021014255.
9
SER-109, an Oral Microbiome Therapy for Recurrent Infection.SER-109，一种用于复发性感染的口腔微生物组疗法。
N Engl J Med. 2022 Jan 20;386(3):220-229. doi: 10.1056/NEJMoa2106516.
10
Enterococcus Intestinal Domination is Associated with Increased Mortality in the Acute Leukemia Chemotherapy Population.肠球菌肠道优势与急性白血病化疗人群死亡率增加有关。
Clin Infect Dis. 2021 Dec 20;78(2):414-22. doi: 10.1093/cid/ciab1043.
Zotero 插件